Literature DB >> 25505254

Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma.

Lauren G Aoude1, Antonia L Pritchard1, Carla Daniela Robles-Espinoza1, Karin Wadt1, Mark Harland1, Jiyeon Choi1, Michael Gartside1, Víctor Quesada1, Peter Johansson1, Jane M Palmer1, Andrew J Ramsay1, Xijun Zhang1, Kristine Jones1, Judith Symmons1, Elizabeth A Holland1, Helen Schmid1, Vanessa Bonazzi1, Susan Woods1, Ken Dutton-Regester1, Mitchell S Stark1, Helen Snowden1, Remco van Doorn1, Grant W Montgomery1, Nicholas G Martin1, Thomas M Keane1, Carlos López-Otín1, Anne-Marie Gerdes1, Håkan Olsson1, Christian Ingvar1, Ake Borg1, Nelleke A Gruis1, Jeffrey M Trent1, Göran Jönsson1, D Timothy Bishop1, Graham J Mann1, Julia A Newton-Bishop1, Kevin M Brown1, David J Adams1, Nicholas K Hayward1.   

Abstract

BACKGROUND: The shelterin complex protects chromosomal ends by regulating how the telomerase complex interacts with telomeres. Following the recent finding in familial melanoma of inactivating germline mutations in POT1, encoding a member of the shelterin complex, we searched for mutations in the other five components of the shelterin complex in melanoma families.
METHODS: Next-generation sequencing techniques were used to screen 510 melanoma families (with unknown genetic etiology) and control cohorts for mutations in shelterin complex encoding genes: ACD, TERF2IP, TERF1, TERF2, and TINF 2. Maximum likelihood and LOD [logarithm (base 10) of odds] analyses were used. Mutation clustering was assessed with χ(2) and Fisher's exact tests. P values under .05 were considered statistically significant (one-tailed with Yates' correction).
RESULTS: Six families had mutations in ACD and four families carried TERF2IP variants, which included nonsense mutations in both genes (p.Q320X and p.R364X, respectively) and point mutations that cosegregated with melanoma. Of five distinct mutations in ACD, four clustered in the POT1 binding domain, including p.Q320X. This clustering of novel mutations in the POT1 binding domain of ACD was statistically higher (P = .005) in melanoma probands compared with population control individuals (n = 6785), as were all novel and rare variants in both ACD (P = .040) and TERF2IP (P = .022). Families carrying ACD and TERF2IP mutations were also enriched with other cancer types, suggesting that these variants also predispose to a broader spectrum of cancers than just melanoma. Novel mutations were also observed in TERF1, TERF2, and TINF2, but these were not convincingly associated with melanoma.
CONCLUSIONS: Our findings add to the growing support for telomere dysregulation as a key process associated with melanoma susceptibility.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505254      PMCID: PMC4334787          DOI: 10.1093/jnci/dju408

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

1.  PTOP interacts with POT1 and regulates its localization to telomeres.

Authors:  Dan Liu; Amin Safari; Matthew S O'Connor; Doug W Chan; Andrew Laegeler; Jun Qin; Zhou Songyang
Journal:  Nat Cell Biol       Date:  2004-06-06       Impact factor: 28.824

2.  Whole-exome sequencing of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes.

Authors:  Kirk E Lohmueller; Thomas Sparsø; Qibin Li; Ehm Andersson; Thorfinn Korneliussen; Anders Albrechtsen; Karina Banasik; Niels Grarup; Ingileif Hallgrimsdottir; Kristoffer Kiil; Tuomas O Kilpeläinen; Nikolaj T Krarup; Tune H Pers; Gaston Sanchez; Youna Hu; Michael Degiorgio; Torben Jørgensen; Annelli Sandbæk; Torsten Lauritzen; Søren Brunak; Karsten Kristiansen; Yingrui Li; Torben Hansen; Jun Wang; Rasmus Nielsen; Oluf Pedersen
Journal:  Am J Hum Genet       Date:  2013-11-27       Impact factor: 11.025

3.  TERT promoter mutations in familial and sporadic melanoma.

Authors:  Susanne Horn; Adina Figl; P Sivaramakrishna Rachakonda; Christine Fischer; Antje Sucker; Andreas Gast; Stephanie Kadel; Iris Moll; Eduardo Nagore; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

4.  TIN2 is a tankyrase 1 PARP modulator in the TRF1 telomere length control complex.

Authors:  Jeffrey Zheng-Sheng Ye; Titia de Lange
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

5.  POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex.

Authors:  Jeffrey Zheng-Sheng Ye; Dirk Hockemeyer; Andrew N Krutchinsky; Diego Loayza; Sarah M Hooper; Brian T Chait; Titia de Lange
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

6.  POT1 as a terminal transducer of TRF1 telomere length control.

Authors:  Diego Loayza; Titia De Lange
Journal:  Nature       Date:  2003-05-25       Impact factor: 49.962

7.  POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.

Authors:  Andrew J Ramsay; Víctor Quesada; Miguel Foronda; Laura Conde; Alejandra Martínez-Trillos; Neus Villamor; David Rodríguez; Agnieszka Kwarciak; Cecilia Garabaya; Mercedes Gallardo; Mónica López-Guerra; Armando López-Guillermo; Xose S Puente; María A Blasco; Elías Campo; Carlos López-Otín
Journal:  Nat Genet       Date:  2013-03-17       Impact factor: 38.330

8.  TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase.

Authors:  Huawei Xin; Dan Liu; Ma Wan; Amin Safari; Hyeung Kim; Wen Sun; Matthew S O'Connor; Zhou Songyang
Journal:  Nature       Date:  2007-01-21       Impact factor: 69.504

9.  Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.

Authors:  Jianxin Shi; Xiaohong R Yang; Bari Ballew; Melissa Rotunno; Donato Calista; Maria Concetta Fargnoli; Paola Ghiorzo; Brigitte Bressac-de Paillerets; Eduardo Nagore; Marie Francoise Avril; Neil E Caporaso; Mary L McMaster; Michael Cullen; Zhaoming Wang; Xijun Zhang; William Bruno; Lorenza Pastorino; Paola Queirolo; Jose Banuls-Roca; Zaida Garcia-Casado; Amaury Vaysse; Hamida Mohamdi; Yasser Riazalhosseini; Mario Foglio; Fanélie Jouenne; Xing Hua; Paula L Hyland; Jinhu Yin; Haritha Vallabhaneni; Weihang Chai; Paola Minghetti; Cristina Pellegrini; Sarangan Ravichandran; Alexander Eggermont; Mark Lathrop; Ketty Peris; Giovanna Bianchi Scarra; Giorgio Landi; Sharon A Savage; Joshua N Sampson; Ji He; Meredith Yeager; Lynn R Goldin; Florence Demenais; Stephen J Chanock; Margaret A Tucker; Alisa M Goldstein; Yie Liu; Maria Teresa Landi
Journal:  Nat Genet       Date:  2014-03-30       Impact factor: 38.330

10.  Rate of de novo mutations and the importance of father's age to disease risk.

Authors:  Augustine Kong; Michael L Frigge; Gisli Masson; Soren Besenbacher; Patrick Sulem; Gisli Magnusson; Sigurjon A Gudjonsson; Asgeir Sigurdsson; Aslaug Jonasdottir; Adalbjorg Jonasdottir; Wendy S W Wong; Gunnar Sigurdsson; G Bragi Walters; Stacy Steinberg; Hannes Helgason; Gudmar Thorleifsson; Daniel F Gudbjartsson; Agnar Helgason; Olafur Th Magnusson; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  72 in total

1.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

2.  A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma.

Authors:  Craig C Teerlink; Chad Huff; Jeff Stevens; Yao Yu; Sheri L Holmen; Mark R Silvis; Kirby Trombetti; Hua Zhao; Douglas Grossman; James M Farnham; Jingran Wen; Julio C Facelli; Alun Thomas; Markus Babst; Scott R Florell; Laurence Meyer; John J Zone; Sancy Leachman; Lisa A Cannon-Albright
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

Review 3.  Stop pulling my strings - what telomeres taught us about the DNA damage response.

Authors:  Eros Lazzerini-Denchi; Agnel Sfeir
Journal:  Nat Rev Mol Cell Biol       Date:  2016-05-11       Impact factor: 94.444

4.  Response.

Authors:  Matthew Bainbridge; Melissa L Bondy
Journal:  J Natl Cancer Inst       Date:  2015-06-16       Impact factor: 13.506

5.  Germline RAD51B truncating mutation in a family with cutaneous melanoma.

Authors:  Karin A W Wadt; Lauren G Aoude; Lisa Golmard; Thomas V O Hansen; Xavier Sastre-Garau; Nicholas K Hayward; Anne-Marie Gerdes
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

Review 6.  [Molecular diagnostics in melanoma].

Authors:  R Lang; J W Bauer; M Laimer
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

Review 7.  Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013-2018).

Authors:  Mijke Visser; Nienke van der Stoep; Nelleke Gruis
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

8.  Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.

Authors:  Michael R Sargen; Donato Calista; David E Elder; Daniela Massi; Emily Y Chu; Míriam Potrony; Ruth M Pfeiffer; Cristina Carrera; Paula Aguilera; Llucia Alos; Susana Puig; Rosalie Elenitsas; Xiaohong R Yang; Margaret A Tucker; Maria Teresa Landi; Alisa M Goldstein
Journal:  J Am Acad Dermatol       Date:  2020-04-10       Impact factor: 11.527

Review 9.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

10.  POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.

Authors:  M Potrony; J A Puig-Butille; M Ribera-Sola; V Iyer; C D Robles-Espinoza; P Aguilera; C Carrera; J Malvehy; C Badenas; M T Landi; D J Adams; S Puig
Journal:  Br J Dermatol       Date:  2019-02-27       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.